公开(公告)号：US08828685B2

公开(公告)日：2014-09-09

申请号：US13577090

申请日：2011-02-04

Applicant: Paul Schimmel ,  Xiang-Lei Yang ,  Bonnie Slike

Inventor： Paul Schimmel ,  Xiang-Lei Yang ,  Bonnie Slike

IPC: C07K14/47 ,  C07K1/107 ,  A61K38/00 ,  A61K38/45 ,  C12P21/00 ,  C12P21/02

CPC classification number: C12N9/93 ,  A61K38/45 ,  C07K16/1045 ,  C07K16/40 ,  C12Y601/01 ,  C12Y601/01001 ,  C12Y601/01002 ,  C12Y601/01006 ,  Y02A50/473

Abstract: Isolated monomelic aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.

Abstract translation: 提供了分离的单体氨酰-tRNA合成酶多肽和具有非规范生物活性的多核苷酸，以及与其相关的组合物和方法。

公开(公告)号：US20130052177A1

公开(公告)日：2013-02-28

申请号：US13577090

申请日：2011-02-04

Applicant: Paul Schimmel ,  Xiang-Lei Yang ,  Bonnie Slike ,  Xiaoling Xu ,  Min Guo

Inventor： Paul Schimmel ,  Xiang-Lei Yang ,  Bonnie Slike ,  Xiaoling Xu ,  Min Guo

IPC: A61K38/45 ,  A61P29/00

CPC classification number: C12N9/93 ,  A61K38/45 ,  C07K16/1045 ,  C07K16/40 ,  C12Y601/01 ,  C12Y601/01001 ,  C12Y601/01002 ,  C12Y601/01006 ,  Y02A50/473

Abstract: Isolated monomelic aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.

Abstract translation: 提供了分离的单体氨酰-tRNA合成酶多肽和具有非规范生物活性的多核苷酸，以及与其相关的组合物和方法。

公开(公告)号：US20180064076A1

公开(公告)日：2018-03-08

申请号：US15695417

申请日：2017-09-05

Applicant: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hee-Sung Park ,  Aerin Yang

IPC: A01K67/027 ,  C12N9/00 ,  C12N15/85

CPC classification number: A01K67/0275 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2217/20 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/03 ,  C12N9/93 ,  C12N15/8509 ,  C12Y601/01006

Abstract: The present invention relates to a mouse (Mus musculus) in which expression and site-specific modification of a target protein is temporally and spatially controlled, and a method for producing the same and the use thereof, and more particularly to a transgenic mouse in which expression of a target protein having a modification attached to a specific position is temporally and spatially controlled as a result of incorporation of an unnatural amino acid. In the mouse according to the present invention, in which site-specific modification of a target protein is temporally and spatially controllable, expression of the target protein having the site-specific modification attached thereto is controllable depending on the timing and/or position of introduction of an unnatural amino acid. Thus, the mouse according to the present invention is useful for studies on the in vivo functions of cellular proteins, various human diseases including cancers and neurodegenerative disorders, new drug discovery, and the like.

公开(公告)号：US09511085B2

公开(公告)日：2016-12-06

申请号：US13059006

申请日：2008-08-18

Applicant: Sunghoon Kim ,  Jin Woo Choi

Inventor： Sunghoon Kim ,  Jin Woo Choi

IPC: C07K16/30 ,  C12N15/113 ,  A61K38/17 ,  A61K39/395 ,  A61K31/7088 ,  C12N9/00 ,  G01N33/50 ,  A61K48/00

CPC classification number: A61K31/7088 ,  A61K48/00 ,  C12N9/93 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/14 ,  C12Y601/01006 ,  G01N33/5017

Abstract: The present invention relates to a novel function of lysyl tRNA synthetase (KRS) which enhances tumor cell migration and affects cancer metastasis via KRS's interaction with laminin receptor (67LR) by its translocation to membrane. More particularly, the present invention relates to a method for modulating cancer metastasis or migration, which comprises regulating intracellular levels of KRS; a composition for preventing or treating cancer; use of expression vector for inhibiting the expression of KRS; a method for preventing or treating cancer; use of an agent for inhibiting an activity of KRS; a method for screening an agent which modulates cancer metastasis or migration; and a method for screening an agent which inhibits the interaction of KRS with 67LR, by said novel function. Thus, KRS can modulate cancer metastasis or migration and furthermore, can modulate intracellular metabolism related to 67LR. The interaction between KRS and 67LR can be used effectively in treating, preventing and/or diagnosing of various diseases or disorders related to the interaction.

Abstract translation: 本发明涉及赖氨酰tRNA合成酶（KRS）的新功能，其通过Kis与层粘连蛋白受体（67LR）的相互作用通过其迁移到膜来增强肿瘤细胞迁移并影响癌症转移。 更具体地，本发明涉及一种调节癌症转移或迁移的方法，其包括调节细胞内KRS水平; 用于预防或治疗癌症的组合物; 使用表达载体抑制KRS的表达; 预防或治疗癌症的方法; 使用抑制KRS活性的药剂; 筛选调节癌症转移或迁移的药物的方法; 以及通过所述新功能筛选抑制KRS与67LR的相互作用的药剂的方法。 因此，KRS可以调节癌症转移或迁移，此外，可以调节与67LR相关的细胞内代谢。 KRS和67LR之间的相互作用可以有效地用于治疗，预防和/或诊断与相互作用相关的各种疾病或病症。

公开(公告)号：US20150132277A1

公开(公告)日：2015-05-14

申请号：US14479637

申请日：2014-10-09

Applicant: THE SCRIPPS RESEARCH INSTITUTE

Inventor： Paul Schimmel ,  Xiang-Lei Yang ,  Bonnie Slike

IPC: C12N9/00 ,  C07K16/40 ,  C07K16/10

CPC classification number: C12N9/93 ,  A61K38/45 ,  C07K16/1045 ,  C07K16/40 ,  C12Y601/01 ,  C12Y601/01001 ,  C12Y601/01002 ,  C12Y601/01006 ,  Y02A50/473

Abstract: Isolated monomeric aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.

Abstract translation: 提供了分离的单体氨酰-tRNA合成酶多肽和具有非规范生物活性的多核苷酸，以及与其相关的组合物和方法。

公开(公告)号：US20170108489A1

公开(公告)日：2017-04-20

申请号：US15334963

申请日：2016-10-26

Applicant: Medicinal Bioconvergence Research Center

Inventor： Sunghoon Kim ,  Jin Woo Choi

IPC: G01N33/50 ,  C12Q1/25

CPC classification number: G01N33/5011 ,  C12Y601/01006

Abstract: The present invention relates to a novel function of lysyl tRNA synthetase, that is, lysyl tRNA synthetase interacts with 67LR through translocation of KRS into plasma membrane, and so enhances tumor (or cancer) cell migration, thereby having an effect on cancer metastasis. More specifically, it relates to method for controlling cancer metastasis or cancer cell migration by modulating an cellular level of lysyl tRNA synthetase, an use of an expression vector comprising a construct inhibiting KRS expression for preventing or treating cancer, an use of an agent inhibiting KRS activity for preventing or treating cancer, a method for screening an agent which modulates cancer metastasis or cancer cell migration, a method for screening an agent inhibiting an interaction between KRS and 67LR. Accordingly, cancer metastasis and cancer cell migration may be controlled using the inventive KRS, further the cellular metabolism related to laminin receptor (67LR) of plasma membrane may be controlled. The relationship between KRS and laminin receptor disclosed in the present invention may be very useful for treatment, prevention and/or diagnosis of various disease related to thereof.

公开(公告)号：US20170073659A1

公开(公告)日：2017-03-16

申请号：US15361698

申请日：2016-11-28

Applicant: Medicinal Bioconvergence Research Center

Inventor： Sunghoon Kim ,  Min-Chul Park ,  Sang-Bum Kim

IPC: C12N9/00

CPC classification number: C12N9/93 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Y601/01006 ,  G01N33/57484 ,  G01N2333/9015

Abstract: The present invention relates to: a lysyl tRNA synthetase (KRS) fragment which comprises an amino acid sequence represented by SEQ ID NO: 1 and is secreted from cancer cells; microvesicles comprising the KRS fragment; and a method for providing information necessary for cancer diagnosis and screening a cancer metastasis inhibiting agent using the same. The present invention can be favorably used in the development of a diagnostic kit for providing information necessary for cancer diagnosis or the development of a cancer metastasis inhibiting agent, and thus is highly industrially applicable.

Abstract translation: 本发明涉及：赖氨酰tRNA合成酶（KRS）片段，其包含由SEQ ID NO：1表示的氨基酸序列，并由癌细胞分泌; 包含KRS片段的微泡; 以及提供癌症诊断和筛选癌症转移抑制剂所需的信息的方法。 本发明可以有利地用于开发用于提供癌症诊断或癌症转移抑制剂的开发所必需的信息的诊断试剂盒，因此在工业上是适用的。

公开(公告)号：US20110189195A1

公开(公告)日：2011-08-04

申请号：US13059006

申请日：2008-08-18

Applicant: Sunghoon Kim ,  Jin Woo Choi

Inventor： Sunghoon Kim ,  Jin Woo Choi

IPC: A61K39/395 ,  C12N5/09 ,  C12N15/63 ,  C07K16/40 ,  A61K31/7088 ,  C12Q1/00 ,  C12Q1/68 ,  A61P35/00 ,  A61P35/04

CPC classification number: A61K31/7088 ,  A61K48/00 ,  C12N9/93 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/14 ,  C12Y601/01006 ,  G01N33/5017

Abstract: The present invention relates to a novel function of lysyl tRNA synthetase (KRS) which enhances tumor cell migration and affects cancer metastasis via KRS's interaction with laminin receptor (67LR) by its translocation to membrane. More particularly, the present invention relates to a method for modulating cancer metastasis or migration, which comprises regulating intracellular levels of KRS; a composition for preventing or treating cancer; use of expression vector for inhibiting the expression of KRS; a method for preventing or treating cancer; use of an agent for inhibiting an activity of KRS; a method for screening an agent which modulates cancer metastasis or migration; and a method for screening an agent which inhibits the interaction of KRS with 67LR, by said novel function. Thus, KRS can modulate cancer metastasis or migration and furthermore, can modulate intra-cellular metabolism related to 67LR. The interaction between KRS and 67LR can be used effectively in treating, preventing and/or diagnosing of various diseases or disorders related to the interaction.

Abstract translation: 本发明涉及赖氨酰tRNA合成酶（KRS）的新功能，其通过Kis与层粘连蛋白受体（67LR）的相互作用通过其迁移到膜来增强肿瘤细胞迁移并影响癌症转移。 更具体地，本发明涉及一种调节癌症转移或迁移的方法，其包括调节细胞内KRS水平; 用于预防或治疗癌症的组合物; 使用表达载体抑制KRS的表达; 预防或治疗癌症的方法; 使用抑制KRS活性的药剂; 筛选调节癌症转移或迁移的药物的方法; 以及通过所述新功能筛选抑制KRS与67LR的相互作用的药剂的方法。 因此，KRS可以调节癌症转移或迁移，此外，可以调节与67LR相关的细胞内代谢。 KRS和67LR之间的相互作用可以有效地用于治疗，预防和/或诊断与相互作用相关的各种疾病或病症。

公开(公告)号：US06492131B1

公开(公告)日：2002-12-10

申请号：US09508370

申请日：2000-03-10

Applicant: Dieter Söll ,  Michael Ibba

Inventor： Dieter Söll ,  Michael Ibba

IPC: C12Q148

CPC classification number: C12N9/93 ,  A61K38/00 ,  A61K39/00 ,  C12Q1/25 ,  C12Y601/01006 ,  G01N2500/00 ,  Y02A50/401

Abstract: A protein with canonical lysyl-tRNA synthetase activity was purified from Methanococcus maripaludis, cloned, and sequenced. The predicted amino acid sequence of the enzyme indicated a novel class I polypeptide structurally unrelated to class II lysyl-tRNA synthetase reported in eubacteria, eukaryotes, and the Crenarchaeote Sulfobus solfataricus. A similar class I polypeptide was isolated from Borrelia burgdorferi, the causative agent of Lyme disease, and an open reading frame encoding a class I-type lysyl-tRNA synthetase was identified in the genome of Treponema pallidum, the causative agent of syphilis. The B. burdorferi gene encoding tRNALysl was cloned and used to make tRNA in vitro. The fundamental difference between pathogen and host in an essential enzyme suggests that class I-type lysyl-tRNA synthetase provides a target for the development of medical and veterinary therapeutics and diagnostics for Borrelia and other microorganism infections.

Abstract translation: 具有典型赖氨酰-tRNA合成酶活性的蛋白质从马鞭草霉菌中纯化，克隆并测序。 酶的预测氨基酸序列表明与真细菌，真核生物和Crenarchaeote Sulfobus solfataricus中报道的II类赖氨酰-tRNA合成酶结构上无关的新一类I多肽。 从勃氏疏螺旋体中分离出类似的I类多肽，其是莱姆病的致病因子，并且在梅毒螺旋体梅毒螺旋体的基因组中鉴定了编码I型赖氨酰-tRNA合成酶的开放阅读框。 克隆编码tRNALys1的布氏梭菌基因，并用于体外制备tRNA。 病原体和宿主在基本酶中的根本区别表明I型赖氨酰-tRNA合成酶为开发Borrelia和其他微生物感染的医学和兽医治疗和诊断提供了目标。